Hoechst Nilandron for metastatic prostate cancer approved Sept. 19; first HMR cancer therapy for U.S.
Executive Summary
HOECHST NILANDRON FOR METASTATIC PROSTATE CANCER AVAILABLE BY LATE OCTOBER as an add-on therapy to surgical or chemical castration. Nilutamide (NDA 20-169) was approved by FDA on Sept. 19. Hoechst Marion Roussel is instituting a sample program in which patients will receive their first month's supply of Nilandron (nilutamide) free-of-charge from Hoechst through physicians' offices.